- NextCure press release (NASDAQ:NXTC): Q2 GAAP EPS of -$11.29.
- Cash, cash equivalents, and marketable securities as of June 30, 2025 were $35.3 million as compared to $68.6 million as of December 31, 2024. The decrease of $33.3 million was primarily due to cash used to fund operations. We expect current financial resources to be sufficient to fund operating expenses and capital expenditures into mid-2026.
NextCure GAAP EPS of -$11.29

Related
OS Therapies files $100M mixed securities shelf
16 minutes ago
0
Skechers tops sales estimates as EMEA outperforms, China lag...
17 minutes ago
0
Petrobras plunges after pouring cold water on extra dividend...
19 minutes ago
0
Mill City Ventures III files to sell 94.03M shares of common...
28 minutes ago
0
Mercer International files $750M mixed securities shelf
29 minutes ago
0
Manitowoc guides to low end of $120M–$145M EBITDA range as t...
30 minutes ago
0
Alamos Gold files $500M mixed securities shelf
31 minutes ago
0
Ellington Financial signals confidence in dividend coverage ...
32 minutes ago
0
DeepMarkit appoints Steve Vanry as interim CEO
33 minutes ago
0
Stillwater Critical Minerals announces additional upsize to ...
34 minutes ago
0
Barnes & Noble Education receives non-compliance notice from...
36 minutes ago
0
Fusion Fuel Green registers 3.24M Class A shares for resale
36 minutes ago
0
TXNM Energy files to sell 3.62M shares of common stock for h...
37 minutes ago
0
Zymeworks signals expanded royalty streams and milestone-dri...
38 minutes ago
0
Skechers Non-GAAP EPS of $0.83 misses by $0.03, revenue of $...
39 minutes ago
0
Pfizer and Arvinas' breast cancer therapy to be reviewed by ...
42 minutes ago
0
Exxon Mobil ends in green after six straight sessions of los...
46 minutes ago
0
CarGurus outlines Marketplace revenue growth of up to 14% fo...
50 minutes ago
0
Tegna surges on report of Nextstar advanced deal talks
51 minutes ago
0
Synlogic files $150M mixed securities shelf
52 minutes ago
0
Popular
اعزام اورژانس هرمزگان به مرز شلمچه
5 days ago
3
© FBT Company 2025. All rights are reserved